Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab

Cetuximab-based chemoimmunotherapy has been the standard of care for recurrent or metastatic squamous cell carcinoma of the head and neck (r/m SCCHN) for more than a decade. To date, no predictive or prognostic biomarkers have been established to further guide the systemic treatment with cetuximab-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Pogorzelski, Michael, Hilser, Thomas, Ting, Saskia C., Kansy, Benjamin, Gauler, Thomas C., Stuschke, Martin, Schmid, Kurt W., Lang, Stephan, Grünwald, Viktor, Schuler, Martin, Kasper, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155676/
https://www.ncbi.nlm.nih.gov/pubmed/34055606
http://dx.doi.org/10.3389/fonc.2021.635096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155676/
https://www.ncbi.nlm.nih.gov/pubmed/34055606
http://dx.doi.org/10.3389/fonc.2021.635096

Ejemplares similares